MISSISSAUGA, ON, September 5, 2017 – Ipsen Biopharmaceuticals Canada Inc., an affiliate of Ipsen SA (Euronext: IPN; ADR: IPSEY), an emerging global biopharmaceutical company, today announced that it has joined the Innovative Medicines Canada (IMC) and appointed Paul Reider as Country Manager, effective immediately, to further strengthen its commitment to patient-driven research and innovation in Canada. Through this strategic membership with IMC and new leadership appointment, Ipsen will further its commitment to meeting the needs of patients with rare and serious diseases throughout Canada.
“This is a new chapter for Ipsen Biopharmaceuticals Canada, as we join forces with IMC to advance innovative medicines under Paul’s leadership. Ipsen shares in IMC’s mission of ensuring that Canadians have access to important treatments, and we look forward to working with this important organization to meet the needs of patients living with rare and serious diseases in
Canada,” said Cynthia Schwalm, President, North American Commercial Operations, Ipsen.
“We are pleased to welcome Ipsen Biopharmaceuticals Canada into the association,” said Innovative Medicines Canada President Pamela Fralick. “We are looking forward to working with this new member to establish a refreshed dialogue with all healthcare stakeholders on ways to ensure Canadians get the medicines they need, when they need them while ensuring system sustainability and economic growth for Canada.”
In addition to forging partnerships across Canada’s healthcare ecosystem with key organizations like IMC, Reider will oversee Ipsen Biopharmaceuticals Canada’s operations across all therapeutic areas and will report directly into Cynthia Schwalm, President, North American Commercial Operations, Ipsen. He will continue to serve as an integral member of both the North American and Global Leadership Teams.
“I am honored to join the Ipsen team in Canada and lead the next phase of our growth in this critical market. As highlighted by our new membership with IMC, we are actively expanding our relationships across Canada in an effort to maintain an unwavering focus on our patients and customers in this important market,” said Paul Reider, Country Manager, Ipsen
Biopharmaceuticals Canada. “I look forward to partnering with our colleagues in North America and globally to drive innovation and deliver solutions as ONE Ipsen.”
Reider’s appointment as Country Manager of Canada follows the promotion of former Country
Manager Lyndal Walker to an international assignment as Chief of Staff to Harout Semerjian,
EVP, President Specialty Care International and Global Franchises, where she will support Ipsen’s global commercial efforts. “I also want to thank Lyndal for her leadership and contributions to Ipsen’s growth in Canada,” added Schwalm.
Prior to this role, Reider served as Vice President, Franchise Head – Endocrinology and Oncology since 2015, where he led Ipsen North America’s largest franchise in terms of revenue and team members. During his two years in this role, Reider grew the Franchise’s net revenue to $247 million in 2016, a 283 percent increase over 2014. Reider received his bachelor’s degree in business administration and MBA from Bowling Green State University.
Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neurosciences and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales close to €1.6 billion in 2016, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,100 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com.
About Ipsen Canada
Located in Mississauga, Ontario, Ipsen Biopharmaceuticals Canada, Inc. is the Canadian affiliate of Ipsen and an integrated business unit within North America. Ipsen Biopharmaceuticals Canada Inc. thrives on teamwork and collaboration, and encourages its employees to innovate. A vital part of the company culture is its close tie with its corporate headquarters in Basking Ridge and Paris, a tie that provides employees with a rich global perspective and a broadened awareness of international cultures and business practices. Ipsen Biopharmaceuticals Canada Inc. encourages employees to share best practices, rewards team players, and facilitates and fosters collaboration within its staff. Every person on its staff is important, and their ideas and insights are critical to Ipsen’s success in Canada and globally. Ipsen is driven by accountability to customers and patients, and strives for operational excellence and innovation. For more information on Ipsen, please visit www.ipsen.ca.
Forward Looking Statements
The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words “believes,” “anticipates” and “expects” and similar expressions are intended to identify forward-looking statements, including the Group’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group’s activities and financial results. The Group cannot be certain that its partners will fulfill their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group’s business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers.
For further information:
Vice President, North American Internal & External
# # #